Seddik, Ahmed H. http://orcid.org/0000-0001-5783-2914
Melzer, Nima
Tsotra, Foteini
Ostwald, Dennis A.
Funding for this research was provided by:
Novartis Pharma
Article History
Accepted: 16 September 2021
First Online: 19 October 2021
Declarations
:
: This study was funded by Novartis Pharma GmbH.
: Ahmed H. Seddik was an employee of WifOR institute by the time of completion of the study and writing the manuscript. Ahmed H. Seddik is currently an employee of Daiichi-Sankyo Europe. Foteini Tsotra is an employee of WifOR institute. Dennis A. Ostwald is the CEO of WifOR institute. Nima Melzer is an employee of Novartis. WifOR institute was commissioned by Novartis Pharma GmbH to conduct this study
: All relevant data for building the study model were reported in the body and annex of the manuscript
: The model and analyses were developed in Excel 365, VBA and R by WifOR institute and are proprietary property of Novartis Pharma GmbH
: Ahmed H. Seddik, Nima Melzer and Dennis A. Ostwald contributed to the design of the model. Ahmed H. Seddik, Nima Melzer and Foteini Tsotra contributed to the manuscript writing. All authors contributed to the interpretation of the data, revised the manuscript critically for important intellectual content and approved the final manuscript.
: Not applicable.
: No applicable.
: Not applicable.